BioHarvest Sciences Inc(BHST) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.52 | Insider Own | 16.12% | Shs Outstand | 22.7M | Perf Week | -7.03% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 36.49% | Insider Trans | - | Shs Float | 14.5M | Perf Month | 18.62% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.14 | Inst Own | 9.97% | Short Float | 0.68% | Perf Quarter | -15.27% |
| Income | -0.01B | P/S | 1.1 | EPS this Y | 12.08% | Inst Trans | -0.46% | Short Ratio | 2.17 | Perf Half Y | -60.73% |
| Sales | 0.04B | P/B | 1.97 | EPS next 5Y | - | ROA | -30.6% | Short Interest | 0.10M | Perf YTD | -66.86% |
| Book/sh | 0.87 | P/C | 2.4 | EPS past 3/5Y | 11.1% 2.26% | ROE | -142.5% | 52W High | -85.9% ($12.20) | Perf Year | -85.55% |
| Cash/sh | 0.72 | P/FCF | - | Sales past 3/5Y | 84.46% 144.37% | ROIC | -33.66% | 52W Low | 25.46% ($1.37) | Perf 3Y | -65.15% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 24.63% | Gross Margin | 58.95% | Volatility(W/M) | 7.09% 8.13% | Perf 5Y | -83.34% |
| Dividend TTM | - | EV/Sales | 1.14 | Sales Y/Y TTM | 17.5% | Oper. Margin | -17.99% | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.75 | EPS Q/Q | 30.37% | Profit Margin | -31.21% | RSI (14) | 52.56 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.24 | Sales Q/Q | 3.78% | SMA20 | 6.71% ($1.61) | Beta | 1.32 | Target Price | $10.5 |
| Payout | - | Debt/Eq | 0.89 | Earnings | 2026/8/11 | SMA50 | -1.28% ($1.74) | Rel Volume | 0.56 | Prev Close | $1.68 |
| Employees | 89 | LT Debt/Eq | 0.66 | EPS/Sales Surpr. | -44.68% -6.5% | SMA200 | -48.31% ($3.33) | Avg Volume(3M) | 0.05M | Price | $1.72 |
| IPO | 2019/3/8 | Option/Short | No/Yes | Trades | 63 | Volume | 25,353 | Change | 2.38% |
🌿 An innovative biotech company that produces high-value plant-derived compounds through its proprietary 'Plant Cell Cultivation (Bio-Plant CELLicitation™)' technology. The company has successfully commercialized 'VINIA®', a health functional food that maximizes the concentration of active ingredients by proliferating plant cells directly in bioreactors without traditional agricultural methods.
Over the past 1 year, on the lower side
86% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
BHST has a sound balance sheet but weak earning power
Of every $100 in sales, $17.99 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +12.1% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $110. Peers typically go for $42.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -83.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 10.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
AIMS Acuitas Small Cap Active ETF <0.01% It ranks #46 of 61 in the industry
Based on market cap of $39M.
BRID#45 Bridgford Foods Corp $50M PER - BHST#46 BioHarvest Sciences Inc $39M PER - 
BOF#47 BranchOut Food Inc $33M PER - 
LSF#48 Laird Superfood Inc $31M PER - 
JVA#49 Coffee Holding Co Inc $26M PER 5.4 
FAQ
What kind of company is BHST?
BHST belongs to the Consumer Defensive sector and operates in the Packaged Foods industry.
What is the market cap of BHST?
The market cap of BHST is approximately $39M, ranking 4,977 within its sector.
What is the 52-week high and low for BHST?
BHST has recorded a 52-week high of $12.20 and a low of $1.37.
